<International Circulation>:From the TRITON study we know that the variation of the response to the drug is quite low in prasugrel versus the clopidogrel，  so is it necessary to perform the platelet function test in the clinical study when you are taking prasugrel?
Prof. Montalesco: No， it is not necessary to do it， it is not even recommended， though the question is still pending. There is one big randomized study looking at monitoring versus no monitoring of patients undergoing PCI: the ARCTIC study.  I am the chairman of this study and I will present this study in the American Heart Association at the first outlined session. So， to answer your question， we needed a randomized study， this randomized study is finished， and will be presented at the American Heart Association.

　　《国际循环》：通过TRITON TIMI-38研究，我们发现与氯吡格雷相比，不同患者对普拉格雷反应性的差别很小，那么在临床实践应用普拉格雷时是否有必要测定血小板功能？
Montalesco教授：是的，没必要，对此甚至没有推荐。但还是有一些问题有待回答。ARCTIC研究在PCI患者观察了监测或不监测血小板功能。我是该研究的主要负责人，将在AHA年会上公布研究结果。应用普拉格雷时是否有必要测定血小板功能这一问题，我们需要一项随机试验，我们已经完成了该试验，结果将在AHA年会上公布。

　　<International Circulation>:That is very good. In the TRILOGY trial the median treatment duration is 18 months. This is quite long. It is longer compared to TRITON and PLATO. Why did you choose such a long duration?
Prof. Montalesco: It is more a study of secondary prevention. Patients were selected several days after the ACS， so the acute phase is finished. With secondary prevention， we usually look at longer follow ups and try to rather evidence over two or three years， so it was done that way here.

　　《国际循环》：TRILOGY-ACS试验的平均治疗时间相当长，达到18个月。比TRITON TIMI-38和PLATO试验都要长。治疗这么长时间的原因是什么？
Montalesco教授：TRILOGY-ACS试验更多的是二级预防研究。ACS患者在起病几天后被入选，因此已经过了急性期。就二级预防来讲，我们通常随访时间更长些，期望得到两、三年随访的证据，因此TRILOGY-ACS试验抗血小板治疗时间较长。

<International Circulation>:In clinical practice I donot think we use that kind of longer duration of DAPT.
Prof. Montalesco:Yes， but it was tested， for example， in CHARISMA at four years follow up with aspirin and clopidogrel. The study was negative， although there was a benefit in MI patients. The PEGASUS study， with ticagalor， is also performing these tests.

　　《国际循环》：临床实践中，我们通常不用那么长时间的抗血小板治疗？
Montalesco教授：没错。不过，CHARISMA随访4年，阿司匹林和氯吡格雷双重抗血小板，结果为阴性，尽管在心梗患者中有获益。PEGASUS试验，则对替格雷洛作了相似的研究。

　　<International Circulation>:Do you support prolonged duration of DAPT?
Prof. Montalesco: For now， it is only for a year， but if the TRILOGY or PEGASUS studies are positive， we may have indications for longer treatment.

　　《国际循环》：你是否支持延长双联抗血小板治疗的时间？
Montalesco教授：目前是治疗1年，但是如果TRILOGY-ACS研究或PEGASUS研究得出阳性结果，就有了延长抗血小板治疗的证据。